Harmony Biosciences Holdings Inc. Common Stock (HRMY)

FairStock Score: 73/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Harmony as a commercial-stage rare-disease business, not a speculative pipeline. It sells WAKIX for narcolepsy, and its pipeline for Prader-Willi and other neurological conditions may add optionality, though the moat rests heavily on one product. The numbers are unusually attractive for a biotech. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $261.3M, net income $75.4M, and diluted EPS $1.28. In fiscal Q2 2025, the quarter ended 2025-06-30, revenue was $200.5M, net income $39.8M, and diluted EPS $0.68, so revenue grew about 30% and profit nearly 89%. For FY2025, revenue was $868.5M and net income $158.7M, versus FY2024 revenue $714.7M and net income $145.5M. FairStock's rules call it a FAST GROWER from filed annual results: profit 46.3% a year over four years and revenue 29.9%. The balance sheet is conservative: D/E 0.16, Altman Z 4.65, Piotroski 6/9, TTM FCF $354.9M, and FCF yield 16.5% at the 2026-10-13 close. FairStock also calculates ROE 20.46% and ROCE 11.62%. At $37.03, P/E is 11.98, P/B 2.15, PEG 0.13, EV/EBITDA 6.29, while Graham Number is $34.57, a -7.12% margin of safety. That is not an asset bargain, but the cash-flow valuation is undemanding. Risks are single-product concentration, pipeline uncertainty, and quarterly lumpiness. I want durable WAKIX sales, trial data, and disciplined capital allocation.

In plain English: Harmony Biosciences is a drug company that sells a treatment for narcolepsy and is developing medicines for rare brain and nerve conditions. The business looks strong: sales and profits are growing quickly, debt is low, and it generates a lot of cash. At $37.03, the stock looks reasonably priced compared with those profits and cash flow, though not deeply discounted by every simple measure.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer